Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.46
-0.04 (-0.47%)
Mar 4, 2026, 2:47 PM EST - Market open
Kura Oncology Employees
Kura Oncology had 192 employees as of December 31, 2024. The number of employees increased by 50 or 35.21% compared to the previous year.
Employees
192
Change (1Y)
50
Growth (1Y)
35.21%
Revenue / Employee
$541,818
Profits / Employee
-$1,129,604
Market Cap
736.17M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 579 |
| Prime Medicine | 214 |
| ProKidney | 204 |
| Lexicon Pharmaceuticals | 103 |
| Theravance Biopharma | 97 |
| enGene Holdings | 82 |
| AgomAb Therapeutics NV | 58 |
KURA News
- 6 days ago - Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 days ago - Kura Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy - Seeking Alpha
- 7 weeks ago - Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - GlobeNewsWire
- 3 months ago - Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript - Seeking Alpha
- 3 months ago - Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - GlobeNewsWire
- 3 months ago - Kura Oncology: A Cautious Buy - Seeking Alpha